Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Eli Lilly has been a terrific stock to own for the past five years, thanks to its excellent clinical and regulatory progress.

As the first earnings season of 2025 unfolds, investors are likely analyzing financial reports to refine their portfolio strategies.